Foghorn Therapeutics (FHTX) Accounts Payables (2019 - 2026)

Foghorn Therapeutics' Accounts Payables history runs 8 years deep, the most recent figure standing at $3.3 million for Q1 2026.

• On a quarterly basis, Accounts Payables fell 18.48% year-over-year to $3.3 million in Q1 2026; TTM through Mar 2026 was $3.3 million, a 18.48% decrease from a year earlier, with the FY2025 full-year figure at $4.3 million, up 12.71% from the prior year.
• Accounts Payables declined to $3.3 million in Q1 2026 per FHTX's latest filing, from $4.3 million in the prior quarter.
• Across five years, Accounts Payables topped out at $7.3 million in Q1 2023 and bottomed at $3.2 million in Q3 2025.
• The 5-year median for Accounts Payables is $4.8 million (2024), against an average of $4.8 million.
• Across the five-year window, Accounts Payables jumped 90.73% in 2023 and sank 46.88% in 2024, its largest moves.
• Year by year, Accounts Payables stood at $5.4 million in 2022, then gained by 15.63% to $6.3 million in 2023, then sank by 39.54% to $3.8 million in 2024, then grew by 12.71% to $4.3 million in 2025, then declined by 22.25% to $3.3 million in 2026.
• Per Business Quant, the three latest FHTX Accounts Payables figures stand at $3.3 million (Q1 2026), $4.3 million (Q4 2025), and $3.2 million (Q3 2025).